EMERYVILLE, Calif. -- NovaCal Pharmaceuticals, Inc. today announced that the FDA has cleared the company's IND for NVC-101, a novel topical anti-microbial product. Dr. Kenneth Krantz, NovaCal's VP of Medical Affairs said that the company plans to begin Phase II clinical trials at four centers early in 2005. "Our trials are aimed at reducing bacterial infection and improving healing in chronic non-healing venous stasis ulcers, as well as in diabetic ulcers and pressure sores."
Infection in chronic wounds is one of the major obstacles to healing encountered by the five million Americans who suffer for months or even years from these debilitating ulcers, where the use of current topical antiseptic products is discouraged by the U.S. Public Health Service because of their cytotoxicity.
Dr. Behzad Khosrovi, NovaCal's VP of Research and Development explained that the in vitro data submitted to the FDA shows that NVC-101 has a broad anti-microbial profile. In addition, the in vivo safety studies showed an acceptable safety profile. He pointed out that "NVC-101 is quite remarkable because of the speed with which it kills gram positive and gram negative bacteria, including the resistant species of MRSA and VRE that are becoming a major problem in hospitals."
NovaCal Pharmaceuticals, Inc. is developing three small molecule anti-microbial compounds for use in a wide range of potential human and veterinary applications. In addition to NVC-101, NVC-320 is in pre-clinical development and a third compound, NVC-422, is a lead pre-clinical candidate. NVC-320 has characteristics that complement those of NVC-101 and should permit its use in different indications. The company is exploring the potential uses for its compounds in dental applications, including periodontitis, ophthalmic indications, severe burns, surgical and dermatological applications, as well as in mastitis in dairy cows. "With such a wide range of potential uses," said Dr. Ron Najafi, Chairman and CEO, "we are beginning discussions with appropriate partners to take our products into the clinic in these additional indications."
Source: NovaCal Pharmaceuticals, Inc.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.